Abstract
TRANSCRIPTIONAL activation of target genes represents an important component of the tumour-suppressor function of p53 and provides a functional link between p53 and various growth-regulatory processes, including cell cycle progression (p21/WAF1)1á¤-3, DNA repair (GADD45)4 and apoptosis (bax)5. Here we use a differential cloning approach to identify the gene encoding insulin-like growth factor binding protein 3 (IGF-BP3) as a novel p53-regulated target gene. Induction of IGF-BP3 gene expression by wild-type but not mutant p53 is associated with enhanced secretion of an active form of IGF-BP3 capable of inhibiting mitogenic signalling by the insulin-like growth factor IGF-1. Our results indicate that IGF-BP3 may link p53 to potential novel autocrine/paracrine signalling pathways and to processes regulated by or dependent on IGF(s), such as cellular growth, transformation and survival.
Similar content being viewed by others
References
El-Deiry, W. S. et al. Cell 75, 817–825 (1993).
Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. Cell 75, 805–816 (1993).
Xiong, Y. et al. Nature 366, 701–704 (1993).
Smith, M. L. et al. Science 266, 1376–1380 (1994).
Miyashita, T. et al. Oncogene 9, 1799–1805 (1994).
Shaw, P. et al. Proc. natn. Acad. Sci. U.S.A. 89, 4495–4499 (1992).
Buckbinder, L., Talbott, R., Seizinger, B. R. & Kley, N. Proc. natn. Acad. Sci. U.S.A. 91, 10640–10644 (1994).
Cubbage, M. L., Suwanichkul, A. & Powell, D. R. J. biol. Chem. 265, 12642–12649 (1990).
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W. & Vogelstein, B. Nature Genet. 1, 45–49 (1992).
Takenaka, I., Morin, F., Seizinger, B. R. & Kley, N. J. biol. Chem. 270, 5405–5411 (1995).
Valentinis, B., Bhala, A., DeAngelis, T., Baserga, R. & Cohen, P. Molec. Endocr. 9, 361–367 (1995).
Jones, J. I. & Clemmons, D. R. Endocr. Rev. 16, 3–34 (1995).
Shimasaki, S. & Ling, N. Progr. Growth Factor Res. 3, 243–266 (1992).
Baserga, R. Cell 79, 927–930 (1994).
Resnicoff, M. et al. Cancer Res. 55, 2463–2469 (1995).
Grigoriev, V. G., Moerman, E. J. & Goldstein, S. J. J. Cell Physiol. 160, 203–211 (1994).
Swisshelm, K., Ryan, K., Tsuchiva, K. & Sager, R. Proc. natn. Acad. Sci. U.S.A. 92, 4472–4476 (1995).
Cohen, P., Peehl, D. M., Graves, H. C. B. & Rosenfeld, R. G. J. Endocr. 142, 407–415 (1994).
Yu, H. et al. Cancer Res. 55, 1603–1606 (1995).
Yu, H. et al. Cancer Res. 55, 2104–2110 (1995).
Harvey, M. et al. Oncogene 8, 2457–2467 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Buckbinder, L., Talbott, R., Velasco-Miguel, S. et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377, 646–649 (1995). https://doi.org/10.1038/377646a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/377646a0
- Springer Nature Limited
This article is cited by
-
Elevated expression of WSB2 degrades p53 and activates the IGFBP3-AKT-mTOR-dependent pathway to drive hepatocellular carcinoma
Experimental & Molecular Medicine (2024)
-
Interaction of lncRNAs with mTOR in colorectal cancer: a systematic review
BMC Cancer (2023)
-
Seryl tRNA synthetase cooperates with POT1 to regulate telomere length and cellular senescence
Signal Transduction and Targeted Therapy (2019)
-
Shifting perspectives from “oncogenic” to oncofetal proteins; how these factors drive placental development
Reproductive Biology and Endocrinology (2018)
-
p53: key conductor of all anti-acne therapies
Journal of Translational Medicine (2017)